Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 23,62 € (+120,13 %). La médiane est de 23,62 € (+120,13 %).
| Acheter |
10 |
| Conserver |
5 |
| Vendre |
1 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Novocure presents turnaround plan with profitability targets and product launches
At the Morgan Stanley Healthcare Conference, Novocure unveiled a three-stage plan to achieve profitability and for the first time provided financial guidance, targeting adjusted EBITDA break-even by the end of 2025. The company reported 8% volume growth in its glioblastoma business, sees further upside in the US, and identifies Japan as its fourth-largest market. New product launches for pancreatic cancer (Optune Pax, CE mark in Europe) and non-small cell lung cancer are expected to drive growth; Novocure stresses it has roughly $440 million of liquidity to execute the plan. » Plus sur de.investing.com
NovoCure: market launches of Optune Pax gain momentum and drive international growth
NovoCure reported at the Wells‑Fargo conference increasing commercial momentum, particularly for Optune Pax in pancreatic cancer with about 600 prescriptions in four months and roughly 285 active patients. The company generated positive cash flow in Q2 2026 for the first time in years and is targeting a clear path to profitability alongside double‑digit revenue growth. Growth drivers also include Optune Gio for glioblastoma and expansion in Japan; risks remain reimbursement, competition from adagrasib, and a recent cybersecurity incident with limited impact. NovoCure is keeping R&D spending around $200 million and plans to hold sales and marketing costs stable, while additional approvals and guideline inclusions should support uptake. » Plus sur de.investing.com
NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices
NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » Plus sur finance.yahoo.com
Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed
The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » Plus sur de.investing.com
NovoCure CEO sells 34,273 shares for about $615,000
Frank Leonard, CEO of NovoCure, reported an open-market sale of 34,273 common shares on June 4, 2026, for roughly $615,000. The sale reduced his direct holdings from 493,793 to 459,520 shares, representing 6.94% of his prior direct stake, and is his largest individual open-market sale to date. No indirect or derivative interests were affected; post-transaction direct holdings were valued at about $8.3 million. » Plus sur finance.yahoo.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 170,74 M | 19,84 % |
| Bénéfice brut | 131,43 M | 25,93 % |
| Bénéfice net | -9,21 M | 70,99 % |
| EBITDA | 1,84 M | 108,18 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,26 Md € |
Nombre d'actions | 116,92 M |
Plus haut/bas sur 52 semaines | 19,48 € - 8,92 € |
| Dividendes | Non |
Bêta | 1,08 |
Ratio P/E | -11,16 |
Ratio PEG | -0,42 |
Ratio P/B | 3,94 |
Ratio P/S | 1,91 |
Profil de l'entreprise
NovoCure Limited, une entreprise d'oncologie, est engagée dans le développement, la fabrication et la commercialisation de dispositifs à champs de traitement tumoral (TTFields) destinés au traitement des cancers solides dans les régions suivantes : États-Unis, Europe, Moyen-Orient, Afrique, Japon et Grande Chine. Ses dispositifs TTFields comprennent Optune, utilisé pour le traitement du glioblastome, et Optune Lua, utilisé pour le traitement du mésothéliome pleural malin. La société mène également des essais cliniques en cours ou achevés portant sur les TTFields dans les métastases cérébrales, le cancer gastrique, le glioblastome, le cancer du foie, le cancer du poumon non à petites cellules, le cancer du pancréas et le cancer de l'ovaire. NovoCure Limited a été constituée en 2000 et son siège social se situe à Saint-Hélier, à Jersey.
| Nom | NovoCure |
| PDG | Frank Leonard |
| Siège social | Baar,
Israël |
| Site web | |
| Secteur | Santé |
| Industrie | Technologies de la santé |
| Introduction en bourse | 01/10/2015 |
| Employés | 1 605 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | NVCR |
Frankfurt | 038.F |
Düsseldorf | 038.DU |
München | 038.MU |